SCHEMBL3257150

SCHEMBL3257150

COc1ccc(Br)cc1C(O)c1ncc(Cl)nc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.38
MALT1 Q9UDY8 2/20 0.36
LMNA P02545 2/20 0.35
RXFP1 Q9HBX9 2/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
PPARG P37231 1/20 0.35
GFER P55789 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.34
HSD17B10 Q99714 2/20 0.34
AMY1A P0DUB6 1/20 0.34
TSHR P16473 1/20 0.34
ADRA2A P08913 2/20 0.33
ADRA1A P35348 2/20 0.33
GLP1R P43220 1/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3253017 0.80 ALDH1A1 (0.39) ACHEMALT1LMNARXFP1ALDH1A1
SCHEMBL4527520 0.78 MALT1 (0.39) MALT1LMNARXFP1ALDH1A1MAPT
SCHEMBL19641019 0.74 ACHE (0.45) ACHELMNAMAPTKMT2AMEN1
SCHEMBL19641289 0.72 CD274 (0.39) ACHE
SCHEMBL4015279 0.71 IGFBP3 (0.43) ALDH1A1HSD17B10IDO1TDO2CYP2D6
SCHEMBL5752891 0.70 HPGD (0.43) LMNAPPARGKMT2AADRA2AADRA1A
SCHEMBL8745945 0.70 ATM (0.48) ACHELMNAALDH1A1MAPTKMT2A
SCHEMBL3254162 0.70 MAPT (0.41) MALT1LMNARXFP1ALDH1A1MAPT
SCHEMBL30677200 0.70 LMNA (0.34) ACHELMNA
SCHEMBL19641027 0.70 LMNA (0.34) ACHELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1833477-B1 PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES NOVARTIS AG (CH) 2010-06-02 EP disclosed
US-20090258874-A1 PYRAZOLO-HETEROARYL COMPOUNDS NOVARTIS AG (CH) 2009-10-15 US disclosed
US-20090258874-A1 PYRAZOLO-HETEROARYL COMPOUNDS NOVARTIS AG (CH) 2009-10-15 US disclosed
US-20090258874-A1 PYRAZOLO-HETEROARYL COMPOUNDS NOVARTIS AG (CH) 2009-10-15 US disclosed
EP-1833477-A1 PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES Novartis AG (CH) 2007-09-19 EP disclosed
WO-2006063820-A1 PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES NOVARTIS AG (CH) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258874-A1 PYRAZOLO-HETEROARYL COMPOUNDS IL1R1, IL1A, IL1B ACHE 3918/4885MALT1 141/4885LMNA 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.